Carbetocin -Retrophin

Drug Profile

Carbetocin -Retrophin

Alternative Names: CYP-2001

Latest Information Update: 02 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nastech Pharmaceutical Company
  • Developer Retrophin
  • Class Oxytocics; Posterior pituitary hormones
  • Mechanism of Action Oxytocin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Autistic disorder

Most Recent Events

  • 26 Aug 2010 Cypress Bioscience acquires patent and technology rights for intranasal carbetocin from Marina Biotech
  • 25 Aug 2010 Marina Biotech is seeking to divest its nasal drug delivery programmes
  • 01 Apr 2010 MDRNA acquires Cequent Pharmaceuticals and is renamed Marina Biotech
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top